Allianz Asset Management
AUTL

Allianz Asset Management’s Autolus Therapeutics AUTL Stock Holding History

Allianz Asset Management’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-38,700
Closed -$135K – 2188
2024
Q2 		$135K Hold
38,700
– – ﹤0.01% 2049
2024
Q1 		$247K Buy
+38,700
New +$241K ﹤0.01% 1803
2021
Q3 		– Sell
-122,680
Closed -$815K – 2541
2021
Q2 		$815K Buy
+122,680
New +$761K ﹤0.01% 1824
2019
Q4 		– Sell
-45,000
Closed -$553K – 2763
2019
Q3 		$553K Buy
45,000
+15,000
+50% +$198K ﹤0.01% 2345
2019
Q2 		$483K Sell
30,000
-9,245
-24% -$207K ﹤0.01% 2362
2019
Q1 		$1.24M Sell
39,245
-6,615
-14% -$188K ﹤0.01% 2023
2018
Q4 		$1.48M Sell
45,860
-20,400
-31% -$671K ﹤0.01% 1880
2018
Q3 		$2.03M Buy
+66,260
New +$1.79M ﹤0.01% 1934

Other funds holding AUTL

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Allianz Asset Management's AUTL Position: Q3 2024 in Review

Allianz Asset Management sold out of Autolus Therapeutics (AUTL) in Q3 2024, closing a stake of 38,700 shares — an estimated $135K sold.

Allianz Asset Management first reported a position in AUTL in Q3 2018 and held it in 8 quarters. The position peaked at $2.03M in Q3 2018. 101 funds tracked by Wall St. Rank hold AUTL as of Q3 2024.

  • Allianz Asset Management reported no remaining Autolus Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Allianz Asset Management sold 38,700 Autolus Therapeutics shares in Q3 2024, an estimated $135K.
  • Allianz Asset Management first reported a position in Autolus Therapeutics in Q3 2018 and held it in 8 quarters.
  • Allianz Asset Management's Autolus Therapeutics position peaked at $2.03M in Q3 2018.
  • 101 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q3 2024.

Based on Allianz Asset Management's 13F filing for Q3 2024, filed 13 Nov 2024.